Table 2.
Clinical and pathological responses
| Variable | n (%) |
| Clinical response | |
| CR | 26 /50 (52.0 %) |
| PR | 18 /50 (36.0 %) |
| SD | 3 /50 (6.0 %) |
| PD | 1 /50 (2.0 %) |
| Unknown | 2 /50 (4.0 %) |
| Pathological response | |
| Overall pCR | 20 /50 (40.0 %) |
| Subtype, pCR | |
| ER+/HER2− | 0 /2 (0.0 %) |
| ER+/HER2+ | 4 /11 (36.4 %) |
| ER−/HER2+ | 3 /9 (33.3 %) |
| ER−/HER2− | 13 /28 (46.4 %) |
| Overall quasi-pCR | 24 /50 (48.0 %) |
| Subtype, quasi-pCR | |
| ER+/HER2− | 1 /2 (50.0 %) |
| ER+/HER2+ | 5 /11 (45.5 %) |
| ER−/HER2+ | 4 /9 (44.4 %) |
| ER−/HER2− | 14 /28 (50.0 %) |
CR: complete response, ER: estrogen receptor, HER2: human epidermal growth factor receptor 2, pCR: pathological complete response, PD: progressive disease, PgR: progesterone receptor, PR: partial response, SD: stable disease.